13th July 2018, Volume 131 Number 1478

Rhys Ponton

In October last year, PHARMAC opened a consultation on the funding of pregabalin in New Zealand.1 Up until now, pregabalin has not been subsidised for use in New Zealand. Now,…

Subscriber content

The full contents of this page is only available to subscribers.

To view this content please login or subscribe

Summary

Pregabalin has recently been made available fully funded in New Zealand. Experience from countries where pregabalin has been used widely, such as the UK, has demonstrated that pregabalin is liable to misuse and is sought after by users from prescribers such as GPs. Pregabalin is misused on its own at high dose, or in combination with other drugs. When used in combination with other drugs, particularly opioids, its synergistic effects may lead to increased risk of overdose. Prescribers, particularly GPs, need to be aware of this misuse potential and to be careful when prescribing to individuals with a history of substance or alcohol misuse, or to patients who present requesting a prescription specifically for pregabalin. All patients prescribed pregabalin should be reviewed regularly to ensure efficacy and safety.

Abstract

Aim

Pregabalin has not been used widely in New Zealand to this point as it has not been funded, but from May 2018 it will be available fully subsidised. This paper intends to highlight the issue of pregabalin misuse, a concern that will be unfamiliar to most clinicians in New Zealand.

Method

A review of the literature of papers documenting the misuse of gabapentin and pregabalin was conducted with a specific focus on pregabalin.

Results

There is a growing body of evidence regarding the potential of misuse of pregabalin. It produces a range of sensations, including euphoria, sedation and dissociation. It is commonly used in conjunction with other drugs, most notably sedatives and opioids, which leads to an additive effect. Although generally safe when taken alone, pregabalin is a growing feature of drug-related deaths.

Conclusion

Prescribers need to be alert to the potential of pregabalin misuse. This should be achieved through prescribing with great care (not prescribing to new or unknown patients; not in response to direct patient requests for it by name; supplying in limited quantities), regular review of patients and stopping treatment, by slow withdrawal, when lack of efficacy is seen.

Author Information

Rhys Ponton, School of Pharmacy, Faculty of Medical and Health Sciences, The University of Auckland, Auckland.

Correspondence

Rhys Ponton, Private Bag 92019, Auckland 1142.

Correspondence Email

r.ponton@auckland.ac.nz

Competing Interests

Nil.

References

  1. PHARMAC. Proposal to fund pregabalin, and change the funded brand of gabapentin and listing restrictions. In: PHARMAC, (ed.). Wellington 2017.
  2. Micheva KD, Taylor CP, Smith SJ. Pregabalin reduces the release of synaptic vesicles from cultured hippocampal neurons. Mol Pharmacol. 2006; 70:467–76.
  3. European Medicines Agency. Lyrica : European Public Assessment Report - Scientific Discussion. London: EMA, 2005.
  4. Crawford P, Ghadiali E, Lane R, Blumhardt L, Chadwick D. Gabapentin as an antiepileptic drug in man. J Neurol Neurosurg Psychiatry. 1987; 50:682–6.
  5. Field MJ, Oles RJ, Lewis AS, McCleary S, Hughes J, Singh L. Gabapentin (neurontin) and S-(+)-3-isobutylgaba represent a novel class of selective antihyperalgesic agents. Br J Pharmacol. 1997; 121:1513–22.
  6. Pfizer NZ. Lyrica Capsules - NZ Data Sheet. Wellington: MEDSAFE NZ, 2016.
  7. New Zealand Formulary. 2018.
  8. Bockbrader HN, Wesche D, Miller R, Chapel S, Janiczek N, Burger P. A comparison of the pharmacokinetics and pharmacodynamics of pregabalin and gabapentin. Clin Pharmacokinet. 2010; 49:661–9.
  9. Hakkinen M, Vuori E, Kalso E, Gergov M, Ojanpera I. Profiles of pregabalin and gabapentin abuse by postmortem toxicology. Forensic Sci Int. 2014; 241:1–6.
  10. Throckmorton DC. Scheduling recommendation for pregabalin. In: Research CfDEa, (ed.). Rockville, MD.: Federal Drug Administration, 2004.
  11. Markowitz JS, Finkenbine R, Myrick H, King L, Carson WH. Gabapentin abuse in a cocaine user: implications for treatment? J Clin Psychopharmacol. 1997; 17:423–4.
  12. Reccoppa L, Malcolm R, Ware M. Gabapentin abuse in inmates with prior history of cocaine dependence. Am J Addict. 2004; 13:321–3.
  13. Schifano F, D’Offizi S, Piccione M, et al. Is there a recreational misuse potential for pregabalin? Analysis of anecdotal online reports in comparison with related gabapentin and clonazepam data. Psychother Psychosom. 2011; 80:118–22.
  14. Spence D. Bad medicine: gabapentin and pregabalin. BMJ. 2013; 347:f6747.
  15. Bonnet U, Scherbaum N. How addictive are gabapentin and pregabalin? A systematic review. Eur Neuropsychopharmacol. 2017; 27:1185–215.
  16. Schjerning O, Rosenzweig M, Pottegard A, Damkier P, Nielsen J. Abuse Potential of Pregabalin: A Systematic Review. CNS Drugs. 2016; 30:9–25.
  17. Baird CR, Fox P, Colvin LA. Gabapentinoid abuse in order to potentiate the effect of methadone: a survey among substance misusers. Eur Addict Res. 2014; 20:115–8.
  18. Lyndon A, Audrey S, Wells C, et al. Risk to heroin users of polydrug use of pregabalin or gabapentin. Addiction. 2017; 112:1580–9.
  19. Office for National Statistics. Deaths related to drug poisoning in England and Wales: 2016 registrations. Newport, South Wales: ONS, 2017.
  20. Maskell PD. Re: Opioids in the UK: what’s the problem? [electronic response to Stannard C. Opioids in the UK: what’s the problem?] BMJ. 2013; 347.
  21. Elliott SP, Burke T, Smith C. Determining the Toxicological Significance of Pregabalin in Fatalities. J Forensic Sci. 2017; 62:169–73.
  22. Advisory Council on the Misuse of Drugs. Advisory Council on the Misuse of Drugs. London2016.
  23. Boden R, Wettermark B, Brandt L, Kieler H. Factors associated with pregabalin dispensing at higher than the approved maximum dose. Eur J Clin Pharmacol. 2014; 70:197–204.
  24. Robinson G, Judson G, Loan R, Bevin T, O’Connor P. Patterns of prescription drug misuse presenting to provincial drug clinics. N Z Med J. 2011; 124:62–7.
  25. Goodman CW, Brett AS. Gabapentin and Pregabalin for Pain - Is Increased Prescribing a Cause for Concern? N Engl J Med. 2017; 377:411–4.
  26. Freynhagen R, Busche P, Konrad C, Balkenohl M. [Effectiveness and time to onset of pregabalin in patients with neuropathic pain]. Schmerz. 2006; 20:285–8, 90–2.
  27. Toth C. Pregabalin: latest safety evidence and clinical implications for the management of neuropathic pain. Ther Adv Drug Saf. 2014; 5:38–56.
  28. Moore RA, Straube S, Wiffen PJ, Derry S, McQuay HJ. Pregabalin for acute and chronic pain in adults. Cochrane Database Syst Rev. 2009: CD007076.
  29. Pfizer UK. Lyrica Capsules - UK Data Sheet. Sandwich, Kent: Pfizer, 2017.
  30. Sussex Partnership NHS Trust; HM Prison Service. Protocol for the management of Pregabalin and Gabapentin use in HMP Lewes. Lewes, UK, 2016.
  31. Gourlay DL, Heit HA, Almahrezi A. Universal precautions in pain medicine: a rational approach to the treatment of chronic pain. Pain Med. 2005; 6:107–12.

Download

The downloadable PDF version of this article is only available to subscribers.

To view this content please login or subscribe